Properties

Properties

Storage and Stability

Manufacturer stability is 36 months. Store at 25°C (77°F) with excursions permitted between 15-30°C (59-86°F). Do not freeze. Aggrastat® is provided in a carton (100 mL vial and 15 mL bolus vial) or foil overpouch (250 mL bag) for protection from light during storage.

GPI Class Comparison

Aggrastat® provides storage and administration conveniences compared to other GPIs.

GPI Class Comparison Properties

GPI Class Comparison Administration

The product information presented in these tables is not necessarily indicative of clinical efficacy, safety or improved treatment outcomes. Please refer to prescribing information for each product.

References

Aggrastat® Prescribing Information; Integrilin Prescribing Information; ReoPro Prescribing Information; Mousa SA et al. J Pharmacol Exp Ther 1998;286:1277-1284; Scarborough RM et al. Circulation 1999;100:437-444; Schneider DJ et al. Br J Clin Pharmacol 2011;72:672-682; Schneider DJ et al. Expert Rev Cardiovasc Ther 2004;2:903-913; Hashemzadeh M et al. Exp Clin Cardiol 2008;13:192-197

IMPORTANT SAFETY INFORMATION

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.

Unite Interactive